课题基金 / 基金详情

Real-time benefit-risk assessment of influenza vaccine exposure across a nationally representative primary care sentinel network

Real-time benefit-risk assessment of influenza vaccine exposure across a nationally representative primary care sentinel network
通过具有全国代表性的初级保健哨点网络对流感疫苗暴露进行实时效益-风险评估
批准号:
2597950
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Key terms: Vaccine administration and dosage, vaccine adverse effects, human influenza, influenza vaccine, telemedicine, vaccine-preventable diseases, immunologic surveillance, sentinel surveillance, public health informatics, clinical informatics Innovation within influenza vaccination has enabled the release of a number of flu vaccine types to counter seasonal flu each year, each with their own unique characteristics. This can span live attenuated vs inactivated methodologies, egg vs cell cultures, trivalent (protective against three strains) vs quadrivalent (protective against four strains) composition and adjuvanted (added ingredients to maximise immune response) vs high-dosage delivery methods. It is necessary to monitor and compare how these vaccines and their characteristics perform each season; doing so in real-time can even lead to in-season rather than post-season composition changes, maximising the effectiveness of flu response both nationally and internationally. Equally, the unprecedented speed of vaccine development achieved this year to counteract critical illness associated with the novel coronavirus (COVID-19) has also been accompanied with intense levels of scrutiny related to their effectiveness over time and associated adverse events of interest (AEI). Influenza vaccines have never amassed this level of public attention, hesitation and politicisation by comparison. In this context, it will be more important than ever to monitor how and when protectiveness of vaccines wane and to identify at-risk demographics for both adverse events of interest and vaccine hesitancy; differentiating these metrics by vaccine brands, batches and characteristics will be key for informing both disease preparedness and response going forwards. As such, informed by robust original research and rigorous literature review, the primary output of this work will be to develop a real-time influenza vaccine benefit-risk (V-BR) platform capable of monitoring the efficacy, uptake and adverse effects associated with different types and brands of influenza vaccines. This platform will leverage data from the Oxford-Royal College of General Practitioners Research and Surveillance Centre (twice weekly extracts of ~ 15,000,000 pseudoanonymised patient records linked to UKHSA virology databases and hospital and death records), the expertise of its underpinning Clinical Informatics and Outcomes Research Group and a combination of daily extracts and direct questionnaire data supplied by the EMIS 'Patient Access' app (~ 10 million registered users).Benefitting from both the 55-year strong legacy of RCGP RSC surveillance, dashboards and observatories and the richness of data offered through patient experience surveys hosted on the Patient Access app, this studentship will be uniquely positioned to generate a world-class influenza V-BR platform. This work also aligns with MRC research priorities (most notably health informatics, disease prevention, stratified medicine and epidemiology and public health) due to its ability to provide insight into how influenza vaccine uptake, adverse effects and efficacy may differ between population groups. Further, by illuminating where vaccine uptake is lowest, where efficacy wavers and/or where post-vaccination adverse effects are most pronounced, this platform will contribute to efforts to reduce vaccine hesitancy and refusal - a WHO and ECDC priority. Finally, the individual differences that may be revealed by this platform will also make a strong case for exploring a more personalised approach to vaccination in the future. As well as becoming responsible for the ongoing maintenance and actioning of this platform, by the studentship's end the student will have established themselves as an expert within the field of vaccine research, will have upskilled in R, SQL, Tableau and PowerBI and will have authored or co-authored a range of high-level research outputs and publications
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
SERS探针诱导TAM重编程调控头颈鳞癌TIME的研究
  • 批准号:
    82360504
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    32万元
  • 批准年份:
    2023
  • 负责人:
    周学军
  • 依托单位:
华蟾素调节PCSK9介导的胆固醇代谢重塑TIME增效aPD-L1治疗肝癌的作用机制研究
  • 批准号:
    82305023
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    王萌
  • 依托单位:
基于MRI的机器学习模型预测直肠癌TIME中胶原蛋白水平及其对免疫T细胞调控作用的研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    李文政
  • 依托单位:
结直肠癌TIME多模态分子影像分析结合深度学习实现疗效评估和预后预测
  • 批准号:
    62171167
  • 项目类别:
    面上项目
  • 资助金额:
    57万元
  • 批准年份:
    2021
  • 负责人:
    姜慧杰
  • 依托单位: